09-06-2020
siam.pukkato / Shutterstock.com
Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
COVId-19, BIO 2020, big pharma, Novartis, Johnson & Johnson, BIO, Boehmert & Boehmert, compulsory licensing, patent pool
Senator calls on Biden to reject COVID IP waiver
02-03-2021
Quercis licenses patents for thromboembolism platform
28-01-2021
South Africa, India urge WTO to waive IP for COVID-19 treatments
08-10-2020
LSPN Connect: When IP and COVID-19 meet
10-07-2020
BIO 2020: AI patents and secrets
16-06-2020
BIO 2020: Building your first patent portfolio
11-06-2020
